icon
icon
icon
icon
Upgrade
Upgrade

News /

Articles /

Sarepta Therapeutics Inc. (SRPT) Plunges 5.92% Amid Fatality Concerns

Mover TrackerTuesday, Apr 8, 2025 8:07 pm ET
1min read

Sarepta Therapeutics Inc. (SRPT) shares plunged 5.92% today, marking the fourth consecutive day of decline, with a total drop of 21.08% over the past four days. The stock price hit its lowest level since November 2017, with an intraday decline of 6.60%.

Sarepta's stock has been under significant pressure due to recent developments in its Elevidys gene therapy program. The company announced a fatality involving a 16-year-old US patient who died of acute liver failure in March 2025. This incident led to a notable decline in Sarepta's stock price, reflecting investor concerns over the safety of the program.

Despite the fatality, the independent data monitoring committee (IDMC) reviewed the benefit-risk profile of Sarepta's Elevidys trials and determined that it remains favorable. This assessment indicates ongoing confidence in the program's potential, although the incident has raised concerns among investors and analysts.

Analysts have responded to these developments with mixed sentiments. Scotiabank analyst Louise Chen maintained a Hold rating for Sarepta, with a price target set at $80.00. Meanwhile, Deutsche Bank Aktiengesellschaft lowered its price target for Sarepta's shares, reflecting cautious investor sentiment and the potential impact of the fatality on the company's future prospects.

These factors combine to create a complex scenario for Sarepta, with significant scrutiny following clinical trial developments and varying analyst perspectives affecting investor confidence. The company will need to navigate these challenges carefully to regain investor trust and stabilize its stock price.

Comments

Add a public comment...
Post
Refresh
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App